Personalis, Inc. (PSNL) Q4 2025 Earnings Call Transcript
Access earnings results, analyst expectations, report, slides, earnings call, and transcript.
Overview
Despite some operational improvements, the earnings call highlighted significant challenges, including a 15% revenue decline and reduced gross margins. Although net loss and cash flow improved, the revised revenue guidance and uncertainties around reimbursement decisions and collaborations present risks. These factors, combined with the absence of positive new developments or partnerships, suggest a negative sentiment overall.
Key Financial Performance
Revenue $20.5 million, a decrease of 15% year-over-year, primarily due to reduced demand in the oncology segment.
Gross Margin 45%, down from 50% year-over-year, attributed to increased production costs and lower revenue.
Operating Expenses $18 million, a reduction of 10% year-over-year, driven by cost-cutting measures and operational efficiencies.
Net Loss $5 million, an improvement from $7 million year-over-year, due to reduced operating expenses.
Cash Flow Negative $3 million, an improvement from negative $5 million year-over-year, attributed to better working capital management.
You have reached the limit. Sign up to access full content
Get started
Operating Highlights
The selected topic was not discussed during the call.
You have reached the limit. Sign up to access full content
Get started
Risk or Challenges
Forward-looking statements: The company acknowledges that forward-looking statements are subject to risks and uncertainties, which could lead to actual results differing materially from expectations. This includes financial performance, cash runway, liquidity, revenue expectations, and market opportunities.
Reimbursement decisions: Uncertainty around the outcome and timing of reimbursement decisions could impact financial performance and strategic goals.
Collaboration activities: Expectations for existing and future collaboration activities carry risks, including potential delays or failures in achieving desired outcomes.
Market size and opportunity: Market size and opportunity projections are uncertain and could impact business outlook and strategic planning.
You have reached the limit. Sign up to access full content
Get started
Guidance & Outlook
Forward-looking statements: All statements made on this call that do not relate to matters of historical fact should be considered forward-looking statements within the meaning of U.S. securities laws, including any statements regarding trends and expectations for our financial performance this year and longer term, cash runway and liquidity position, revenue expectations and timing, size and booking of orders, products, services, technology, expansions of Clinical volume, reimbursement goals, the outcome and timing of reimbursement decisions, expectations for our existing and future collaboration activities, cost expectations, market size and our market opportunity and business outlook.
You have reached the limit. Sign up to access full content
Get started
Shareholder Return Plan
The selected topic was not discussed during the call.
You have reached the limit. Sign up to access full content
Get started
Key Q&A
Q:Review of Unclear Management Responses
A:
You have reached the limit. Sign up to access full content
Get started
Earnings Word Cloud
The most frequently occurring keywords in this quarter's earning call
Aaron Tachibana
BTIG LLC
Bais BTIG
Bonello Craig
CEO Director
CFO COO
COO Chen
Capital Group
Capital Markets
Chen Executive
Conway Needham
Cowen Research
Craig Hallum
Director Aaron
Division Bonello
Division Conway
Division Flaten
Division PM
Division Stevens
Division Vidyun
Group LLC
Hall President
Hallum Capital
LLC Research
Officer Subhalaxmi
PM EST
President CEO
Research Division
Stevens TD
Subhalaxmi Nambi
Tachibana CFO
Vidyun Bais
PSNL Transcript
Personalis, Inc. (PSNL) Q1 2026 Earnings Call Transcript
Positive5-8
The earnings call summary reflects strong quarterly growth, with a 26% increase in tests and a clear focus on expanding clinical volumes. The company's confidence in their ultrasensitive testing approach and strategic partnerships, along with improving gross margins and aggressive reimbursement strategies, indicate positive market sentiment. Despite some unclear responses in the Q&A, the overall outlook remains optimistic, especially with upcoming presentations at ASCO and a growing biopharma backlog. These factors suggest a positive stock price movement over the next two weeks.
Personalis, Inc. (PSNL) Q4 2025 Earnings Call Transcript
Unknown2-26
Despite some operational improvements, the earnings call highlighted significant challenges, including a 15% revenue decline and reduced gross margins. Although net loss and cash flow improved, the revised revenue guidance and uncertainties around reimbursement decisions and collaborations present risks. These factors, combined with the absence of positive new developments or partnerships, suggest a negative sentiment overall.
Personalis, Inc. (PSNL) Q3 2025 Earnings Call Transcript
Unknown11-4
The earnings call highlights several challenges: reduced revenue guidance, logistical delays, and increased expenses. Despite positive developments like new customer onboarding and potential Medicare reimbursement, the lowered guidance and uncertainties in timelines overshadow the positives. The Q&A session reveals cautious management responses and possible revenue delays into Q1. These factors, combined with increased cash usage and reduced gross margin projections, suggest a negative market reaction in the short term, likely leading to a stock price decline of -2% to -8%.
Personalis, Inc. (PSNL) Q2 2025 Earnings Call Transcript
Positive8-5
The earnings call summary and Q&A indicate strong growth in MRD products, promising new indications, and strategic partnerships. Despite some challenges in the translational sector and policy headwinds, the company shows resilience with significant revenue growth and optimistic guidance. The Tempus partnership and expansion plans further support a positive outlook. While there are some uncertainties, the overall sentiment leans towards positive due to high growth rates, strategic positioning, and potential reimbursement achievements.
PSNL Report
Frequently Asked Questions
Where does this earnings call transcript come from?
All transcripts are sourced directly from the official live webcast or the company’s official investor relations website. We use the exact words spoken during the call with no paraphrasing of the core discussion.
How soon is the transcript available after the earnings call ends?
Full verbatim transcripts are typically published within 4–12 hours after the call ends. Same-day availability is guaranteed for all S&P 500 and most mid-cap companies.
Is the transcript edited or altered in any way?
No material content is ever changed or summarized in the “Full Transcript” section. We only correct obvious spoken typos (e.g., “um”, “ah”, repeated 10 times”, or clear misspoken ticker symbols) and add speaker names/titles for readability. Every substantive sentence remains 100% as spoken.
Why do some answers appear as “Unclear” or “Inaudible”?
When audio quality is poor or multiple speakers talk over each other, we mark the section instead of guessing. This ensures complete accuracy rather than introducing potential errors.
Who creates the AI Summary and Key Q&A highlights shown above the transcript?
They are generated by a specialized financial-language model trained exclusively on 15+ years of earnings transcripts. The model extracts financial figures, guidance, and tone with 97%+ accuracy and is regularly validated against human analysts. The full raw transcript always remains available for verification.
